{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-036281","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.888486+00:00","generated_at":"2026-05-31T10:58:19.719981+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Roivant Q1 net income $57.5M, cash $5.7B; pipeline advances in MG, DM, NIU","bullets":["Net income of $57.5M vs net loss of $327.8M YoY; diluted EPS $0.12 vs ($0.38).","Total revenue $55.1M, product revenue $18.4M from VTAMA; license/milestone $36.8M.","Cash, cash equivalents and restricted cash $5.7B at June 30, 2024, reflecting $648M share repurchase.","Immunovant completed enrollment in batoclimab pivotal MG trial; brepocitinib Phase 3 VALOR in DM completed enrollment.","Priovant to initiate Phase 3 for brepocitinib in NIU; VTAMA PDUFA action expected Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-036281","json":"https://secwatch.observer/filing/0001140361-24-036281.json","markdown":"https://secwatch.observer/filing/0001140361-24-036281.md","text":"https://secwatch.observer/filing/0001140361-24-036281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124036281/0001140361-24-036281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124036281/ef20033756_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:58:19.719981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}